Spots Global Cancer Trial Database for folfoxiri
Every month we try and update this database with for folfoxiri cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer | NCT03487939 | Colorectal Neop... Drug Therapy | FOLFOXIRI | 18 Years - 75 Years | China Medical University, China | |
| Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells | NCT01640405 | Metastatic Colo... | modified FOLFOX... FOLFOXIRI + Bev... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | NCT03117972 | Metastatic Colo... | FOLFOXIRI FOLFOX FOLFIRI Bevacizumab LV5FU2 Capecitabine | 18 Years - 76 Years | Centre Hospitalier Universitaire de Besancon | |
| Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer | NCT03085992 | Rectal Cancer | FOLFOXIRI plus ... Chemoradiothera... | 18 Years - 75 Years | Azienda Ospedaliero, Universitaria Pisana | |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | NCT05253846 | Locally Advance... | Irinotecan Oxaliplatin Lederfolin 5-Fluorouracil Short-course ra... TME | 18 Years - 70 Years | Gruppo Oncologico del Nord-Ovest | |
| Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers | NCT05194878 | Colon Cancer St... Colon Cancer St... | neoadjuvant che... Colectomy adjuvant chemot... | 18 Years - 75 Years | Sun Yat-sen University | |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | NCT05253846 | Locally Advance... | Irinotecan Oxaliplatin Lederfolin 5-Fluorouracil Short-course ra... TME | 18 Years - 70 Years | Gruppo Oncologico del Nord-Ovest | |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases | NCT04832776 | Liver Metastasi... | Cetuximab Bevacizumab FOLFOXIRI | 18 Years - 75 Years | Fudan University | |
| ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) | NCT06242418 | Colon Cancer | FOLFOXIRI XELOX | 18 Years - 75 Years | West China Hospital | |
| Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer | NCT03443661 | Locally Advance... | FOLFOXIRI | 18 Years - 70 Years | ChineseAMS | |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | NCT04097444 | Metastatic Colo... | Bevacizumab 5-fluorouracil Leucovorin calc... Irinotecan hydr... Oxaliplatin Capecitabine | 20 Years - | Chugai Pharmaceutical | |
| FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | NCT02128425 | Metastatic Colo... | FOLFOXIRI FOLFOX | 18 Years - 75 Years | Sun Yat-sen University | |
| FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | NCT03721653 | Metastatic Colo... | Bevacizumab Irinotecan Oxaliplatin L-Leucovorin 5-fluorouracil Atezolizumab | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | NCT01328171 | Metastatic Colo... | FOLFOXIRI + Pan... FOLFOXIRI | 18 Years - | AIO-Studien-gGmbH | |
| FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | NCT01219920 | Metastatic Colo... | FOLFIRI FOLFOXIRI | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | NCT04380337 | Rectal Cancer | FOLFOXIRI FOLFOX regimen XELOX IMRT | 18 Years - | Stanford University | |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | NCT04097444 | Metastatic Colo... | Bevacizumab 5-fluorouracil Leucovorin calc... Irinotecan hydr... Oxaliplatin Capecitabine | 20 Years - | Chugai Pharmaceutical | |
| Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer | NCT02217020 | Rectal Cancer | FOLFOXIRI | 18 Years - 70 Years | Sun Yat-sen University | |
| Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer | NCT05201430 | Rectal Cancer | FOLFOXIRI CapeOX | 18 Years - 75 Years | Fudan University | |
| Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation | NCT03671252 | Rectal Cancer | FOLFOXIRI XELOX Chemoradiothera... TME operation efficacy evalua... | 18 Years - 75 Years | Sun Yat-sen University | |
| Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | NCT00689624 | Metastatic Colo... | Irinotecan Leukovorin Oxaliplatin 5-FLUOROURACIL Cetuximab | 18 Years - 70 Years | University Hospital of Crete | |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient | NCT02295930 | Metastatic Colo... | folfoxiri+cetux... folfoxiri+cetux... | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | NCT05200299 | Colorectal Canc... | mFOLFOXIRI mFOLFOX6 OR Cap... | 18 Years - 75 Years | First Affiliated Hospital of Wenzhou Medical University | |
| The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | NCT03711240 | Colorectal Canc... | bevacizumab Oxaliplatin Irinotecan Leucovorin 5-FU | 20 Years - 75 Years | National Cheng-Kung University Hospital | |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | NCT04097444 | Metastatic Colo... | Bevacizumab 5-fluorouracil Leucovorin calc... Irinotecan hydr... Oxaliplatin Capecitabine | 20 Years - | Chugai Pharmaceutical | |
| FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | NCT02128425 | Metastatic Colo... | FOLFOXIRI FOLFOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | NCT03117972 | Metastatic Colo... | FOLFOXIRI FOLFOX FOLFIRI Bevacizumab LV5FU2 Capecitabine | 18 Years - 76 Years | Centre Hospitalier Universitaire de Besancon | |
| The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | NCT03711240 | Colorectal Canc... | bevacizumab Oxaliplatin Irinotecan Leucovorin 5-FU | 20 Years - 75 Years | National Cheng-Kung University Hospital | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | NCT03391843 | Rectal Cancer S... | FOLFOXIRI+Cetux... | 18 Years - 75 Years | RenJi Hospital | |
| FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type | NCT02350530 | Metastatic Colo... | FOLFOXIRI + Bev... FOLFOXIRI | 18 Years - 70 Years | Sun Yat-sen University | |
| Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer | NCT05362825 | Liver Metastasi... Synchronous Neo... | Neo-adjuvant Ch... synchronous res... | 18 Years - 75 Years | Cho Ray Hospital | |
| mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer | NCT04338191 | Colorectal Canc... | mFOLFOXIRI adju... mFOLFOX6 adjuva... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | NCT02515734 | Colorectal Canc... | fluorouracil Leucovorin irinotecan oxaliplatin bevacizumab cetuximab | 20 Years - | Japan Clinical Cancer Research Organization | |
| Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | NCT00689624 | Metastatic Colo... | Irinotecan Leukovorin Oxaliplatin 5-FLUOROURACIL Cetuximab | 18 Years - 70 Years | University Hospital of Crete | |
| Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer | NCT05362825 | Liver Metastasi... Synchronous Neo... | Neo-adjuvant Ch... synchronous res... | 18 Years - 75 Years | Cho Ray Hospital | |
| Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer | NCT03487939 | Colorectal Neop... Drug Therapy | FOLFOXIRI | 18 Years - 75 Years | China Medical University, China | |
| Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer | NCT03085992 | Rectal Cancer | FOLFOXIRI plus ... Chemoradiothera... | 18 Years - 75 Years | Azienda Ospedaliero, Universitaria Pisana | |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer | NCT03484221 | Rectal Neoplasm... Drug Therapy Radiation | FOLFOXIRI Short-Course Ra... XELOX | 18 Years - 75 Years | China Medical University, China | |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient | NCT02295930 | Metastatic Colo... | folfoxiri+cetux... folfoxiri+cetux... | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | NCT03391843 | Rectal Cancer S... | FOLFOXIRI+Cetux... | 18 Years - 75 Years | RenJi Hospital | |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | NCT05253846 | Locally Advance... | Irinotecan Oxaliplatin Lederfolin 5-Fluorouracil Short-course ra... TME | 18 Years - 70 Years | Gruppo Oncologico del Nord-Ovest |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
